Cargando…
Azilsartan: Current Evidence and Perspectives in Management of Hypertension
Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP). To this end, emergence of more...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925743/ https://www.ncbi.nlm.nih.gov/pubmed/31885897 http://dx.doi.org/10.1155/2019/1824621 |
_version_ | 1783481964961988608 |
---|---|
author | Pradhan, Akshyaya Tiwari, Ashish Sethi, Rishi |
author_facet | Pradhan, Akshyaya Tiwari, Ashish Sethi, Rishi |
author_sort | Pradhan, Akshyaya |
collection | PubMed |
description | Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP). To this end, emergence of more potent antihypertensive drugs is a welcome sign. Angiotensin receptor blockers (ARBs) are cornerstones of hypertension management in daily practice. Among all ARBs, azilsartan is proven to be more potent in most of the head-to-head trials till date. Azilsartan is the latest ARB approved for hypertension with greater potency and minimal side effects. This review highlights the role of azilsartan in management of hypertension in the current era. |
format | Online Article Text |
id | pubmed-6925743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-69257432019-12-29 Azilsartan: Current Evidence and Perspectives in Management of Hypertension Pradhan, Akshyaya Tiwari, Ashish Sethi, Rishi Int J Hypertens Review Article Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP). To this end, emergence of more potent antihypertensive drugs is a welcome sign. Angiotensin receptor blockers (ARBs) are cornerstones of hypertension management in daily practice. Among all ARBs, azilsartan is proven to be more potent in most of the head-to-head trials till date. Azilsartan is the latest ARB approved for hypertension with greater potency and minimal side effects. This review highlights the role of azilsartan in management of hypertension in the current era. Hindawi 2019-11-03 /pmc/articles/PMC6925743/ /pubmed/31885897 http://dx.doi.org/10.1155/2019/1824621 Text en Copyright © 2019 Akshyaya Pradhan et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Pradhan, Akshyaya Tiwari, Ashish Sethi, Rishi Azilsartan: Current Evidence and Perspectives in Management of Hypertension |
title | Azilsartan: Current Evidence and Perspectives in Management of Hypertension |
title_full | Azilsartan: Current Evidence and Perspectives in Management of Hypertension |
title_fullStr | Azilsartan: Current Evidence and Perspectives in Management of Hypertension |
title_full_unstemmed | Azilsartan: Current Evidence and Perspectives in Management of Hypertension |
title_short | Azilsartan: Current Evidence and Perspectives in Management of Hypertension |
title_sort | azilsartan: current evidence and perspectives in management of hypertension |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925743/ https://www.ncbi.nlm.nih.gov/pubmed/31885897 http://dx.doi.org/10.1155/2019/1824621 |
work_keys_str_mv | AT pradhanakshyaya azilsartancurrentevidenceandperspectivesinmanagementofhypertension AT tiwariashish azilsartancurrentevidenceandperspectivesinmanagementofhypertension AT sethirishi azilsartancurrentevidenceandperspectivesinmanagementofhypertension |